Systematic (IUPAC) name | |
---|---|
(7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
Clinical data | |
Trade names | Spectracef |
AHFS/Drugs.com | monograph |
MedlinePlus | a605003 |
Pregnancy cat. | ? |
Legal status | ? |
Identifiers | |
CAS number | 104145-95-1 |
ATC code | J01DD16 |
PubChem | CID 9870843 |
ChemSpider | 8046534 |
UNII | 81QS09V3YW |
KEGG | D07639 |
ChEBI | CHEBI:59343 |
Chemical data | |
Formula | C19H18N6O5S3 |
Mol. mass | 506.58 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Cefditoren is also marketed under the name Meiact.[1]
Contents |
Cefditoren is used to treat uncomplicated skin and skin structure infections, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis (ABECB), pharyngitis, and tonsillitis.
Cefditoren is available as 200 and 400 mg tablets. It can be formulated as the prodrug cefditoren pivoxil.